Request a quote

Cell Therapy Analytical Development and Quality Control Services

uBriGene provides comprehensive analytical development and QC testing services for a variety of cell therapy products, ensuring safety, efficacy, and regulatory compliance.

Request a quote
Cell therapy services hero banner

Robust Cell Therapy Analytical and QC Testing Platform

Our robust cell therapy analytical development and testing platform provides cell product-specific analytical and testing methods, including CAR-T, CAR-NK, TCR-T, TIL, iPSC, and MSC therapies.

As a cell therapy manufacturing CDMO with extensive experience, we deliver high-quality, compliant, and reliable cell therapy analytical method development and QC testing to ensure the safety and efficacy of cell products.

Cell Therapy AD/QC Testing Highlights

Platform Technology Testing

Manufactured and QC released 100+ cell batches
Compendial and validated assays
Build customized product-specific testing plans

Comprehensive AD/QC Testing

Purity testing
Safety testing
Potency testing

Extensive Cell Therapy Expertise

CAR-T, CAR-NK, CAR-TCR, iPSC, MSC
Provide critical technical, regulatory, and strategic support
Tech transfer services

Strong Regulatory Compliance

Adherence to global guidelines: FDA, EMA, CDE
10+ IND clearances annually, FDA & NMPA
10+ DMF filed
Need help with cell therapy analytical development and QC testing

Need Help with Cell Therapy Analytical Development & QC Testing?

Ensure the safety, quality, and regulatory compliance of your cell therapy products with uBriGene’s expert analytical development and QC testing services.

Contact the Experts

CAR-T, CAR-NK, TIL, iPSC, MSC CDMO Manufacturing Services

Extensive experience
Closed and automated systems
Accelerate your therapeutic programs into the clinic
Contact the Experts
CDMO services for CAR-T, CAR-NK, TIL, iPSC and MSC

CAR-T, TCR-T, and CAR-NK Analytical Development and Testing

uBriGene provides comprehensive assays for CAR-T, TCR-T, and CAR-NK analytics and QC release. Key analytical and QC testing include assessing cell identity, viability, potency, and functionality, as well as confirming genetic modification accuracy and stability.

Additional testing focuses on detecting impurities, such as residual viral vectors or unwanted cell populations, and ensuring compliance with regulatory standards. Robust testing ensures the safety and efficacy of CAR-T, TCR-T, and CAR-NK products for clinical success.

Analytical and QC testing categories for CAR-T, TCR-T, and CAR-NK:

Purity/Identity: CD3 (T cells), CD56 (NK cells)

Strength/Potency: cell viability, transgene expression, cell killing assay, cytokine release assay
Residual: BSA, E1A, SV40, RetroNectin, Magnetic beads, tumor cell
Safety: Viral copy number, Endotoxin, sterility, mycoplasma, replication-competent virus

Induced Pluripotent Stem Cell (iPSC) Analytical Development and Testing

As a CDMO specializing in iPSC generation, uBriGene has developed robust analytical development and quality control assays. iPSC testing is essential to ensuring the safety, quality, and functionality of iPSC-derived products for cell therapy and regenerative medicine. Key tests include assessments of pluripotency, genetic stability, and differentiation potential to confirm that iPSCs can reliably produce the desired cell types.

Additional tests focus on identity, purity, sterility, and safety, including tumorigenicity and off-target differentiation. Rigorous analytical methods and QC standards are essential to meet regulatory requirements and ensure the consistency and efficacy of iPSC-based therapies.

Safety assays: Mycoplasma, endotoxin, sterility
Cell Viability
Pluripotency assay – Flow cytometry and embryoid body formation
Outsourced testing management: STR, Karyotyping, adventitious virus

Featured Resources

CAR-T Webinar

Explore the basics of CAR-T therapies, from foundations to manufacturing.

CRISPR Webinar

explore the future of CRISPR technology and how we’re solving key manufacturing challenges.

RNA-LNP Brochure

Redefining RNA Therapeutics: GMP RNA-LNP Manufacturing You Can Trust

LVV Turbo™ Brochure

Discover Lentivirus (LVV) production processes and testing.

Frequently asked questions

Analytical testing ensures the safety, potency, purity, and identity of cell therapy products, meeting regulatory standards and guaranteeing therapeutic efficacy. It also identifies impurities or contaminants that could compromise product quality or patient safety.

We specialize in testing CAR-T, CAR-NK, TIL, iPSC, and MSC-based therapies, providing tailored analytical development and QC testing to meet the unique requirements of each platform.

Key tests include identity verification, viability assays, potency testing, microbial testing, endotoxin detection, and mycoplasma screening. Advanced methods like flow cytometry and molecular assays are also utilized.

Yes, our experienced cell therapy analytical development scientists can provide custom assay development and validation services tailored to your cell therapy product’s unique needs, ensuring compliance with regulatory guidelines.

Yes, we conduct storage stability studies under various conditions to assess cell viability, potency, and quality over time, helping establish product shelf life and storage conditions. We can also help with cell therapy rapid QC release for fresh cell products.

Potency testing is conducted through functional assays such as cytotoxicity assays, cytokine release assays, and target cell-killing assays, depending on the cell therapy product’s mechanism of action.

Yes, we offer flow cytometry-based CAR expression assays to confirm the functionality and surface expression of CAR constructs in modified cells.

Turnaround times depend on the specific assays and project complexity. We work closely with clients to establish timelines that align with their development and manufacturing schedules.

We leverage advanced technologies such as flow cytometry, qPCR, ELISA, next-generation sequencing (NGS), and high-performance liquid chromatography (HPLC).

Detection of CAR-positive cells can be achieved using Protein L or specific antibodies targeting the SCFV or VHH domain of the CAR. Universal antibodies recognizing constant regions, such as G4S or Whitlow linker sequences, are also commonly used.

TIL quality control evaluates product identity, purity, potency, and safety. Key safety tests include sterility, endotoxin, and mycoplasma testing to detect contamination that could compromise product quality or patient safety. The testing strategy should also assess TIL identity, viability, and functional activity according to the product's intended use and release requirements.

uBriGene assesses iPSC pluripotency using flow cytometry to quantify surface markers (SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81), immunocytochemistry to detect OCT4, NANOG, SSEA-4, and TRA-1-60, and embryoid body formation to evaluate differentiation into cells from all three germ layers. These complementary methods characterize iPSC pluripotency for research and regenerative medicine applications.

CAR-T cell in vitro cytotoxicity can be evaluated using LDH release assays, flow cytometry (FACS), cell viability assays (MTT/CCK-8), real-time cell analysis (RTCA), clonogenic assays, or ELISPOT, depending on the target cells and study objectives.

uBriGene primarily uses flow cytometry with distinguishable target cell lines to quantify CAR-T-mediated target cell killing. Customized assay designs are available to meet specific research needs and support CAR-T therapy development.

uBriGene supports iPSC characterization through pluripotency marker analysis by flow cytometry, embryoid body formation, and immunocytochemistry. Additional testing can include STR genotyping, karyotype analysis, sterility, mycoplasma, endotoxin, and adventitious virus testing. The testing plan depends on the cell product, development stage, and intended application.

Yes. uBriGene's cell therapy analytical services include support for rapid QC release testing for fresh cell products. Testing requirements and turnaround times depend on the assays needed, product characteristics, and release schedule; the testing plan should be established with the analytical team.

Leverage uBriGene’s Cell Therapy AD/QC Expertise

Partner with our cell therapy experts to ensure the safety, efficacy, and regulatory compliance of your therapeutic programs.
Request a quote
Need help with cell therapy analytical development and QC testing